GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipigon Pharmaceuticals AB (OSTO:LPGO) » Definitions » Institutional Ownership

Lipigon Pharmaceuticals AB (OSTO:LPGO) Institutional Ownership : 0.00% (As of May. 20, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lipigon Pharmaceuticals AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lipigon Pharmaceuticals AB's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lipigon Pharmaceuticals AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lipigon Pharmaceuticals AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Lipigon Pharmaceuticals AB Institutional Ownership Historical Data

The historical data trend for Lipigon Pharmaceuticals AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipigon Pharmaceuticals AB Institutional Ownership Chart

Lipigon Pharmaceuticals AB Historical Data

The historical data trend for Lipigon Pharmaceuticals AB can be seen below:

2023-05-31
Institutional Ownership 0.01

Lipigon Pharmaceuticals AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Lipigon Pharmaceuticals AB (OSTO:LPGO) Business Description

Traded in Other Exchanges
Address
Tvistevagen 48 C, Umea, SWE, 90736
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.

Lipigon Pharmaceuticals AB (OSTO:LPGO) Headlines

No Headlines